Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade

BACKGROUND: While immune checkpoint blockade (ICB) is the current first-line treatment for metastatic melanoma, it is effective for ~ 52% of patients and has dangerous side effects. The objective here was to identify the feasibility and mechanism of RAS/RAF/PI3K pathway inhibition in melanoma to sen...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Chi, Saleh, Nabil, Yang, Jinming, Nebhan, Caroline A., Vilgelm, Anna E., Reddy, E. Premkumar, Roland, Joseph T., Johnson, Douglas B., Chen, Sheau-Chiann, Shattuck-Brandt, Rebecca L., Ayers, Gregory D., Richmond, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182921/
https://www.ncbi.nlm.nih.gov/pubmed/34092233
http://dx.doi.org/10.1186/s12943-021-01366-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182921/
https://www.ncbi.nlm.nih.gov/pubmed/34092233
http://dx.doi.org/10.1186/s12943-021-01366-y

Ejemplares similares